Testing tovorafenib plus rituximab for hairy cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug combination (tovorafenib and rituximab) for people with hairy cell leukemia (HCL) whose cancer has a specific genetic change called BRAF V600E. It looks at safety and how well the drugs work, both for people who have had treatment before and for those who have not.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have hairy cell leukemia with the BRAF V600E mutation.
- For the first part of the study, you must have had at least one prior treatment with a purine analog (such as fludarabine, pentostatin, or cladribine).
- For the second part, you must have had no prior treatment for HCL.
- You must be at least 18 years old.
- Your blood counts or symptoms must show that treatment is needed, such as low neutrophil count, low platelets, low hemoglobin, or other signs like infections or enlarged spleen.
- You must be willing to use effective contraception during and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called binimetinib in people with a type of leukemia that has come back or not responded to treatment. It is for those whose cancer cells do not have a BRAF mutation.
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
This study tests whether a combination of targeted drugs (vemurafenib and obinutuzumab) works better than a standard chemo-immunotherapy combination (cladribine and rituximab) for people newly diagnosed with hairy cell leukemia. If you have the BRAF V600E mutation and meet blood count criteria, you may be eligible to join.
This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.
This trial tests a combination of two targeted drugs, rituximab and zanubrutinib, for people with hairy cell leukemia or its variant. It aims to see if this therapy works for those who have already had one type of chemotherapy or who cannot take a standard treatment called purine analogs.
This trial tests a targeted pill called venetoclax for people whose hairy cell leukemia has returned after other treatments. It aims to see if venetoclax can help control the disease and improve blood counts.
Hear when a new Hairy Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.